← All companies

NYMX

Nymox Pharmaceutical Corporation

NYMXF OTC In Vitro & In Vivo Diagnostic Substances EDGAR ↗

$0.02

+0.00 0.00%

Key statistics

from XBRL data in SEC filings

Market cap

$1.89M

Revenue (TTM)

—

Net income (TTM)

—

EPS (TTM)

—

P/E ratio

—

Dividend yield

—

Free cash flow

—

Cash

—

Total assets

—

Gross margin

—

52-week range

$0.01 – $0.20

Recent SEC filings

40 most recent

Annual, quarterly & current reports

6-K FORM 6-K Jun 3, 2026 6-K FORM 6-K Mar 27, 2026 6-K FORM 6-K Nov 7, 2025 6-K FORM 6-K Oct 22, 2025 6-K FORM 6-K Oct 22, 2025 6-K FORM 6-K Sep 23, 2025 20-F FORM 20-F Jun 3, 2025 6-K FORM 6-K May 22, 2025 6-K FORM 6-K Mar 11, 2025 6-K FORM 6-K Jan 2, 2025 6-K FORM 6-K Dec 17, 2024 20-F FORM 20-F Aug 29, 2024 6-K FORM 6-K Jul 18, 2024 6-K FORM 6-K Jul 16, 2024 6-K FORM 6-K May 13, 2024 6-K FORM 6-K Mar 28, 2024 6-K FORM 6-K Nov 15, 2023 6-K FORM 6-K Nov 9, 2023 6-K FORM 6-K Nov 6, 2023 6-K FORM 6-K Oct 26, 2023 6-K FORM 6-K Sep 25, 2023 6-K FORM 6-K Aug 29, 2023 6-K FORM 6-K Aug 14, 2023 6-K FORM 6-K Aug 2, 2023 6-K FORM 6-K Jul 31, 2023 6-K FORM 6-K Jul 25, 2023 6-K FORM 6-K Jul 25, 2023 6-K FORM 6-K Jul 12, 2023 6-K FORM 6-K Jul 6, 2023 6-K FORM 6-K Jun 29, 2023 6-K/A FORM 6-K/A Jun 29, 2023 6-K FORM 6-K Jun 27, 2023 6-K FORM 6-K May 12, 2023 20-F FORM 20-F May 2, 2023 6-K FORM 6-K Jan 6, 2023 6-K/A FORM 6-K/A Nov 16, 2022 6-K/A FORM 6-KA Nov 16, 2022 6-K FORM 6-K Nov 14, 2022 6-K FORM 6-K Nov 14, 2022 6-K FORM 6-K Aug 15, 2022